Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-27T02:27:48.004Z Has data issue: false hasContentIssue false

Do extrapyramidal syndromes influence the patients' mortality?

Published online by Cambridge University Press:  16 April 2020

J. Modestin
Affiliation:
Psychiatric University Hospital, Zurich, Switzerland
M. Vogt Wehrli
Affiliation:
Psychiatric University Hospital, Zurich, Switzerland
P. Agarwalla
Affiliation:
Psychiatric University Hospital, Zurich, Switzerland
P.L. Stephan
Affiliation:
Psychiatric University Hospital, Zurich, Switzerland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In 1994, all patients hospitalized in the Psychiatric University Hospital of Zurich and treated with regular neuroleptics (n = 200) were examined with regard to the prevalence of Parkinson syndrome, akathisia, and tardive dyskinesia. In 2003/04, the patients were traced and re-examined. Out of 200 patients, a total of 63 (31.5%) had died. The group of deceased patients was compared with the group of patients still alive with regard to several socio-demographic variables and the presence of extrapyramidal syndromes at the first examination. As it could have been expected, the patients who died were older and suffered more frequently from organic disorders; further, women were over-represented in this group. Neither group differed with regard to the presence of akathisia and tardive dyskinesia; however, Parkinson symptoms were found to be more pronounced in the deceased group. Thus, Parkinson syndrome due to neuroleptic treatment appears to be a possible risk factor contributing to a higher mortality amongst psychiatric patients.

Type
Poster Session 1: Antipsychotic Medications
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.